Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations

Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies

Yasemin Sahbaz, Tri Hung Nguyen, Leigh Ford, Claire L. McEvoy, Hywel D. Williams, Peter J. Scammells, Christopher J.H. Porter

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

This study aimed to transform weakly acidic poorly water-soluble drugs (PWSD) into ionic liquids (ILs) to promote solubility in, and the utility of, lipid-based formulations. Ionic liquids (ILs) were formed directly from tolfenamic acid (Tolf), meclofenamic acid, diclofenac, and ibuprofen by pairing with lipophilic counterions. The drug-ILs were obtained as liquids or low melting solids and were significantly more soluble (either completely miscible or highly soluble) in lipid based, self-emulsifying drug delivery systems (SEDDS) when compared to the equivalent free acid. In vivo assessment of a SEDDS lipid solution formulation of Tolf didecyldimethylammonium salt and the same formulation of Tolf free acid at low dose (18 mg/kg, where the free acid was soluble in the SEDDS), resulted in similar absorption profiles and overall exposure. At high dose (100 mg/kg), solution SEDDS formulations of the Tolf ILs (didecyldimethylammonium, butyldodecyldimethylammonium or didecylmethylammonium salts) were possible, but the lower lipid solubility of Tolf free acid dictated that administration of the free acid was only possible as a suspension in the SEDDS formulation or as an aqueous suspension. Under these conditions, total drug plasma exposure was similar for the IL formulations and the free acid, but the plasma profiles were markedly different, resulting in flatter, more prolonged exposure profiles and reduced Cmax for the IL formulations. Isolation of a weakly acidic drug as an IL may therefore provide advantage as it allows formulation as a solution SEDDS rather than a lipid suspension, and in some cases may provide a means of slowing or sustaining absorption. The current studies compliment previous studies with weakly basic PWSD and demonstrate that transformation into highly lipophilic ILs is also possible for weakly acidic compounds.

Original languageEnglish
Pages (from-to)3669-3683
Number of pages15
JournalMolecular Pharmaceutics
Volume14
Issue number11
DOIs
Publication statusPublished - 6 Nov 2017

Keywords

  • drug delivery
  • in vitro digestion
  • ionic liquid
  • lipid formulation
  • lipolysis
  • poorly water-soluble drug
  • SEDDS

Cite this

@article{916d1de9b58849e1be6d3336596ec6ca,
title = "Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies",
abstract = "This study aimed to transform weakly acidic poorly water-soluble drugs (PWSD) into ionic liquids (ILs) to promote solubility in, and the utility of, lipid-based formulations. Ionic liquids (ILs) were formed directly from tolfenamic acid (Tolf), meclofenamic acid, diclofenac, and ibuprofen by pairing with lipophilic counterions. The drug-ILs were obtained as liquids or low melting solids and were significantly more soluble (either completely miscible or highly soluble) in lipid based, self-emulsifying drug delivery systems (SEDDS) when compared to the equivalent free acid. In vivo assessment of a SEDDS lipid solution formulation of Tolf didecyldimethylammonium salt and the same formulation of Tolf free acid at low dose (18 mg/kg, where the free acid was soluble in the SEDDS), resulted in similar absorption profiles and overall exposure. At high dose (100 mg/kg), solution SEDDS formulations of the Tolf ILs (didecyldimethylammonium, butyldodecyldimethylammonium or didecylmethylammonium salts) were possible, but the lower lipid solubility of Tolf free acid dictated that administration of the free acid was only possible as a suspension in the SEDDS formulation or as an aqueous suspension. Under these conditions, total drug plasma exposure was similar for the IL formulations and the free acid, but the plasma profiles were markedly different, resulting in flatter, more prolonged exposure profiles and reduced Cmax for the IL formulations. Isolation of a weakly acidic drug as an IL may therefore provide advantage as it allows formulation as a solution SEDDS rather than a lipid suspension, and in some cases may provide a means of slowing or sustaining absorption. The current studies compliment previous studies with weakly basic PWSD and demonstrate that transformation into highly lipophilic ILs is also possible for weakly acidic compounds.",
keywords = "drug delivery, in vitro digestion, ionic liquid, lipid formulation, lipolysis, poorly water-soluble drug, SEDDS",
author = "Yasemin Sahbaz and Nguyen, {Tri Hung} and Leigh Ford and McEvoy, {Claire L.} and Williams, {Hywel D.} and Scammells, {Peter J.} and Porter, {Christopher J.H.}",
year = "2017",
month = "11",
day = "6",
doi = "10.1021/acs.molpharmaceut.7b00442",
language = "English",
volume = "14",
pages = "3669--3683",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "11",

}

Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations : Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies. / Sahbaz, Yasemin; Nguyen, Tri Hung; Ford, Leigh; McEvoy, Claire L.; Williams, Hywel D.; Scammells, Peter J.; Porter, Christopher J.H.

In: Molecular Pharmaceutics, Vol. 14, No. 11, 06.11.2017, p. 3669-3683.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations

T2 - Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies

AU - Sahbaz, Yasemin

AU - Nguyen, Tri Hung

AU - Ford, Leigh

AU - McEvoy, Claire L.

AU - Williams, Hywel D.

AU - Scammells, Peter J.

AU - Porter, Christopher J.H.

PY - 2017/11/6

Y1 - 2017/11/6

N2 - This study aimed to transform weakly acidic poorly water-soluble drugs (PWSD) into ionic liquids (ILs) to promote solubility in, and the utility of, lipid-based formulations. Ionic liquids (ILs) were formed directly from tolfenamic acid (Tolf), meclofenamic acid, diclofenac, and ibuprofen by pairing with lipophilic counterions. The drug-ILs were obtained as liquids or low melting solids and were significantly more soluble (either completely miscible or highly soluble) in lipid based, self-emulsifying drug delivery systems (SEDDS) when compared to the equivalent free acid. In vivo assessment of a SEDDS lipid solution formulation of Tolf didecyldimethylammonium salt and the same formulation of Tolf free acid at low dose (18 mg/kg, where the free acid was soluble in the SEDDS), resulted in similar absorption profiles and overall exposure. At high dose (100 mg/kg), solution SEDDS formulations of the Tolf ILs (didecyldimethylammonium, butyldodecyldimethylammonium or didecylmethylammonium salts) were possible, but the lower lipid solubility of Tolf free acid dictated that administration of the free acid was only possible as a suspension in the SEDDS formulation or as an aqueous suspension. Under these conditions, total drug plasma exposure was similar for the IL formulations and the free acid, but the plasma profiles were markedly different, resulting in flatter, more prolonged exposure profiles and reduced Cmax for the IL formulations. Isolation of a weakly acidic drug as an IL may therefore provide advantage as it allows formulation as a solution SEDDS rather than a lipid suspension, and in some cases may provide a means of slowing or sustaining absorption. The current studies compliment previous studies with weakly basic PWSD and demonstrate that transformation into highly lipophilic ILs is also possible for weakly acidic compounds.

AB - This study aimed to transform weakly acidic poorly water-soluble drugs (PWSD) into ionic liquids (ILs) to promote solubility in, and the utility of, lipid-based formulations. Ionic liquids (ILs) were formed directly from tolfenamic acid (Tolf), meclofenamic acid, diclofenac, and ibuprofen by pairing with lipophilic counterions. The drug-ILs were obtained as liquids or low melting solids and were significantly more soluble (either completely miscible or highly soluble) in lipid based, self-emulsifying drug delivery systems (SEDDS) when compared to the equivalent free acid. In vivo assessment of a SEDDS lipid solution formulation of Tolf didecyldimethylammonium salt and the same formulation of Tolf free acid at low dose (18 mg/kg, where the free acid was soluble in the SEDDS), resulted in similar absorption profiles and overall exposure. At high dose (100 mg/kg), solution SEDDS formulations of the Tolf ILs (didecyldimethylammonium, butyldodecyldimethylammonium or didecylmethylammonium salts) were possible, but the lower lipid solubility of Tolf free acid dictated that administration of the free acid was only possible as a suspension in the SEDDS formulation or as an aqueous suspension. Under these conditions, total drug plasma exposure was similar for the IL formulations and the free acid, but the plasma profiles were markedly different, resulting in flatter, more prolonged exposure profiles and reduced Cmax for the IL formulations. Isolation of a weakly acidic drug as an IL may therefore provide advantage as it allows formulation as a solution SEDDS rather than a lipid suspension, and in some cases may provide a means of slowing or sustaining absorption. The current studies compliment previous studies with weakly basic PWSD and demonstrate that transformation into highly lipophilic ILs is also possible for weakly acidic compounds.

KW - drug delivery

KW - in vitro digestion

KW - ionic liquid

KW - lipid formulation

KW - lipolysis

KW - poorly water-soluble drug

KW - SEDDS

UR - http://www.scopus.com/inward/record.url?scp=85033392023&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.7b00442

DO - 10.1021/acs.molpharmaceut.7b00442

M3 - Article

VL - 14

SP - 3669

EP - 3683

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 11

ER -